Allergy Therapeutics PLC
Company Profile
Business description
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
Contact
Dominion Way
WorthingWest SussexBN14 8SA
GBRT: +44 1903844700
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2026
Employees
576
Stocks News & Analysis
stocks
The best way to get rich and retire early
stocks
Investors overly negative on cheap ASX share
stocks
Overvalued US AI play reports earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,069.00 | 14.40 | -0.16% |
| CAC 40 | 8,103.58 | 0.27 | -0.00% |
| DAX 40 | 24,340.06 | 56.09 | 0.23% |
| Dow JONES (US) | 48,731.16 | 288.75 | 0.60% |
| FTSE 100 | 9,870.68 | 18.54 | -0.19% |
| HKSE | 25,818.93 | 44.79 | 0.17% |
| NASDAQ | 23,613.31 | 51.46 | 0.22% |
| Nikkei 225 | 50,344.10 | 68.77 | -0.14% |
| NZX 50 Index | 13,529.06 | 11.33 | 0.08% |
| S&P 500 | 6,932.05 | 22.26 | 0.32% |
| S&P/ASX 200 | 8,762.70 | 21.10 | -0.24% |
| SSE Composite Index | 3,940.95 | 20.97 | 0.53% |